FIGURE 4.

The expression of TGF‐β/smad2 is enhanced in peritoneal metastatic lesions (A) compared with gastric cancer (GC) patients without PM, GC patients with PM exhibited significantly enhanced expression of NNMT and TGF‐β/smad2 in peritoneal metastatic lesions. (B) IHC staining showed that the expression of TGF‐β and Smad2 was obviously elevated in peritoneal lesions in GC patients with PM compared with that in peritoneal lesions in GC patients without PM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the indicated group